|
|
|
European Biopharmaceutical Review
|
Cellular therapies – such as treatment with mesenchymal stem cells (MSCs) or, recently, with genetically adapted T-autologous (Ta) cells – are coming of age and have exhibited their efficacy for selected indications in numerous preclinical trials. Many have received first approvals or are likely to in the near future. MSCs have been approved for selected indications in Canada as well as New Zealand, and at least one chimeric antigen receptor (CAR) T-cell product has gained a unanimous positive review by the FDA advisory committee.
The cross-section of medical devices and cellular therapies has been explored and utilised for some time; for example, cells have been embedded in collagenous foams to secure their location, or catheters have been employed to facilitate targeted delivery of cells.
For biologics and small molecules, this cross-section is perhaps not as clearly visible, yet it has transpired that combinations may yield massive improvements, as demonstrated in preclinical studies. Hence, this appears to be an opportunity worthy of exploration due to its benefits as well as its practical, quality and regulatory implications.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Digitalisation solutions for a connected plant: Bridging the gap for Pharma 4.0
Digitalisation solutions for a connected plant: Bridging the gap for
Pharma 4.0 Digital transformation is key in ensuring the flexibility,
resilience and agility required in pharmaceutical manufacturing, but
traditionally, the industry has been resistant to digitalisation. Now,
regulatory bodies are pushing for manufacturers to embrace Pharma 4.0
and to incorporate automation into their operations. Here, Alexandra
Hughes, Industry Sales Manager at automation software supplier,
COPA-DATA UK, explains how its zenon automation integration layer (AIL)
can support the digital transformation of pharmaceutical manufacturing
and bridge the gap between brownfield and greenfield equipment.
More info >> |
|
 |
White Papers |
 |
|
Assessing the Integrity of Pharmaceutical Packaging Using the Sepha Blisterscan and Conventional Blue Dye Leak Testing Methods
Sepha Limited
A new whitepaper by a leading packaging expert from the University of Ulster, Dr Dorian Dixon, into the integrity of pharmaceutical packaging has established that existing methods for testing the seal integrity of blister packs are not as accurate as newer, technology based test equipment.
More info >> |
|
|
